Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Cboe BZX - 04/23 05:22:56 pm
59.615 USD   +1.33%
04:54pMERCK AND : Climbs on Goldman Upgrade
AQ
04/22MERCK AND : Pivotal Phase 3 Study of Merck’s Investigational B..
PU
04/20MERCK AND : Advances Clean Energy Goals with Invenergy
AQ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Merck & Co., Inc. : Merck On Track to File Application for Insomnia Drug This Year

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/13/2012 | 02:52pm CEST
   By Victoria Stilwell 
 

Merck & Co. (MRK) said it is on track to file a new drug application for its experimental insomnia medicine this year, making the drug one of six major filings planned for 2012 and 2013.

Data from a Phase 3 clinical trial showed Merck's insomnia drug suvorexant reduced the time it took patients to fall asleep and increased the time patients stayed asleep as early as the first night and at the three-month point compared with a placebo.

The drug met statistical significance on 15 out of 16 primary endpoints. The findings were to be presented at the Annual Meeting of the Associated Professional Sleep Societies.

Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin.

Merck reported in April first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth.

Shares closed at $38.43 Tuesday and were inactive in premarket trade. The stock is up 8.8% in the past 12 months.

Write to Victoria Stilwell at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
04:54pMERCK AND : Climbs on Goldman Upgrade
AQ
04/22MERCK AND : Pivotal Phase 3 Study of Merck’s Investigational Beta-Lactamas..
PU
04/20MERCK AND : Advances Clean Energy Goals with Invenergy
AQ
04/20MERCK AND : Announces First Phase Three Studies for PCV-15 its Investigational P..
AQ
04/19MERCK AND : P&G Boasts Better Bottom Line
AQ
04/19MERCK AND : Biothera Pharmaceuticals Presents Translational Data from Ongoing Cl..
AQ
04/19LEAP THERAPEUTICS : Presents Nonclinical and Clinical Data on DKN-01 at AACR 201..
AQ
04/19MERCK AND : AstraZeneca and Merck - Updated Overall Survival Data for LYNPARZA i..
AQ
04/19MERCK AND : KEYTRUDA plus Pemetrexed and Platinum Chemotherapy Reduced the Risk ..
AQ
04/19MERCK AND : KEYTRUDA Reduced the Risk of Disease Recurrence or Death by More tha..
AQ
More news
News from SeekingAlpha
09:04aPremarket analyst action - healthcare 
08:00aHow To Retire At 65 With Only Half A Million 
02:48aDoes Dicerna's Settlement Agreement With Alnylam Make It A Buy? 
04/21STOCKS TO WATCH : Earnings Blockbusters And Trump Talks Drug Prices 
04/19Novartis Q1 results weigh on pharma stocks 
Financials ($)
Sales 2018 41 911 M
EBIT 2018 13 848 M
Net income 2018 8 764 M
Debt 2018 13 777 M
Yield 2018 3,30%
P/E ratio 2018 18,56
P/E ratio 2019 15,38
EV / Sales 2018 4,11x
EV / Sales 2019 3,94x
Capitalization 159 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 67,9 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Roy D. Baynes Chief Medical Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY4.55%158 571
JOHNSON & JOHNSON-9.35%339 783
PFIZER1.13%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%191 890
AMGEN-1.35%114 648